SDGR short squeeze - it's AI drug discovery season!

{"summary": "Author is long SDGR as the cleanest AI drug discovery play, citing its Bunsen AI agent, Novo Nordisk partnership, and a short squeeze setup.", "reason": "SDGR is explicitly named and the author gives own directional long judgment with fundamental rationale (AI drug discovery pure-play, Bunsen, Novo partnership) and concrete catalyst (short squeeze, 11 days to cover).", "ideas": [{"symbol": "SDGR", "direction": "long", "thesis": "The author argues SDGR is the cleanest pure-play in AI drug discovery, with real technology including the Bunsen AI drug discovery agent that drew positive attention at a Morgan Stanley investment conference, and partnerships with large pharmas such as Novo Nordisk. The stock is up over 50% this week and shorts are caught, with 11 days to cover, which the author expects to fuel continued squeeze momentum for a week or two. The author is long 6,500 shares and may sell if it hits $60. Main risk is the squeeze unwinding or the AI narrative fading.", "thesis_short": "Long SDGR AI drug discovery short squeeze", "quote": "SDGR is pretty much the cleanest play in AI drug discovery.", "confidence": 0.75, "sentiment": 0.8, "timeframe": "week or two"}], "model": "deepseek-flash", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}